Immunotherapy for colorectal cancer:a challenge to clinical trial design

This publication has 32 references indexed in Scilit:

• Fluorouracil and Leucovorin with or without Interferon Alfa-2a as Adjuvant Treatment, in Patients with High-Risk Colon Cancer
  Oncology, 2000
• Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-α-2c in patients with advanced colorectal cancer: final results of a randomised phase III study
  European Journal Of Cancer, 1999
• Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
  The Lancet, 1999
• Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte–macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity
  Gene Therapy, 1998
• Selection for β2-microglobulin mutation in mismatch repair-defective colorectal carcinomas
  Current Biology, 1996
• Preoperative lnterleukin-2 Subcutaneous Immunotherapy May Prolong the Survival Time in Advanced Colorectal Cancer Patients
  Oncology, 1996
• Clinical outcome of colorectal cancer patients treated with human monoclonal anti‐idiotypic antibody
  International Journal of Cancer, 1994
• Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression
  International Journal of Cancer, 1993
• CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
  Nature, 1992
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987